{
    "body": "What is the mechanism of action of Osimertinib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27861144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27393507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27923714", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26902828", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27835594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27912836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26620497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27885838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27196753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26515464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27660466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27071706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27649127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26720671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26898616", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26943236"
    ], 
    "ideal_answer": [
        "Osimertinib is a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation."
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
    ], 
    "type": "summary", 
    "id": "58848822e56acf517600000c", 
    "snippets": [
        {
            "offsetInBeginSection": 761, 
            "offsetInEndSection": 1004, 
            "text": "In addition, mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620497", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 308, 
            "offsetInEndSection": 598, 
            "text": "Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912836", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 243, 
            "offsetInEndSection": 429, 
            "text": "Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071706", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 381, 
            "text": "PURPOSE: Osimertinib (AZD9291) 80\u00a0mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and dosing interval, whether a fixed-dosing approach can be used globally, and the impact of formulation and food on exposure.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902828", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 540, 
            "offsetInEndSection": 649, 
            "text": "RECENT FINDINGS: Third-generation TKIs in clinical development include osimertinib, rociletinib, and HM61713.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26720671", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 580, 
            "offsetInEndSection": 790, 
            "text": "In this study, we investigated the interaction between ABCB1 and osimertinib, a novel selective, irreversible third-generation EGFR TKI that has recently been approved by the U.S. Food and Drug Administration. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1532, 
            "offsetInEndSection": 1758, 
            "text": "Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 159, 
            "offsetInEndSection": 682, 
            "text": "In our study, we investigated whether osimertinib (AZD9291), a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation, could reverse MDR induced by ABCB1 and ABCG2 in vitro, in vivo, and ex vivo Our results showed that osimertinib significantly increased the sensitivity of ABCB1- and ABCG2-overexpressing cells to their substrate chemotherapeutic agents in vitro and in the model of ABCB1-overexpressing KBv200 cell xenograft in nude mice. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196753", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 542, 
            "offsetInEndSection": 771, 
            "text": "The potency of 1st (erlotinib), 2nd (afatinib) and 3rd (osimertinib and rociletinib) generation EGFR-TKIs was compared in vitro for human lung cancer cell lines and Ba/F3 cells, which exogenously express mutated or wild type EGFR", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515464", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 409, 
            "offsetInEndSection": 561, 
            "text": "Osimertinib (AZD9291, Tagrisso\u2122), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660466", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 850, 
            "offsetInEndSection": 1003, 
            "text": "Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898616", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 900, 
            "offsetInEndSection": 1039, 
            "text": "We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943236", 
            "endSection": "abstract"
        }
    ]
}